tetano
Editor, Senior Moderator
Front Neurol
. 2021 Dec 6;12:794471.
doi: 10.3389/fneur.2021.794471. eCollection 2021.
The Effect of Isotonic Saline Nasal Lavages in Improving Symptoms in SARS-CoV-2 Infection: A Case-Control Study
Giacomo Spinato[SUP] 1 [/SUP], Cristoforo Fabbris[SUP] 2 [/SUP], Giulio Costantini[SUP] 3 [/SUP], Federica Conte[SUP] 3 [/SUP], Pier Giorgio Scotton[SUP] 2 [/SUP], Francesco Cinetto[SUP] 1 [/SUP], Rosalba De Siati[SUP] 1 [/SUP], Alessandro Matarazzo[SUP] 1 [/SUP], Marco Citterio[SUP] 1 [/SUP], Giacomo Contro[SUP] 1 [/SUP], Cosimo De Filippis[SUP] 1 [/SUP], Carlo Agostini[SUP] 1 [/SUP], Enzo Emanuelli[SUP] 2 [/SUP], Paolo Boscolo-Rizzo[SUP] 4 [/SUP], Daniele Frezza[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mainly colonizes nasopharynx. In upper airways acute infections, e.g., the common cold, saline nasal irrigations have a significant efficacy in reducing symptoms. The present study aimed to test the efficacy of nasal lavages in upper airways symptoms of Coronavirus Disease 2019 (COVID-19). Methods: A series of consecutive adult subjects who tested positive for SARS-CoV-2 from December 2020 to February 2021 performed daily nasal lavages with saline solution (Lavonase®-Purling, Lugo di Romagna, Italy) for 12 days, starting on the day after the SARS-CoV-2 positive swab. A control group included a historical series of patients who were infected in February-March 2020 and who did not perform lavages. An ad hoc questionnaire regarding symptoms was administered to each subjects at base-line and 10 days after diagnosis (i.e., on the same day of the control swab) in both cases and controls. Results: A total of 140 subjects were enrolled. 68 participants in the treatment group and 72 in the control group were included. 90% of respondents declared the lavages were simple to use and 70% declared they were satisfied. Symptoms of blocked nose, runny nose, or sneezing decreased by an average of 24.7% after the treatment. Blocked nose and sneezing increased in the same period of time in the control group. Ears and eyes symptoms, anosmia/ageusia symptoms, and infection duration (10.53 days in the treatment group and 10.48 days in the control group) didn't vary significantly among the two groups. Conclusion: Nasal lavages resulted to significantly decrease nasal symptoms in newly diagnosed SARS-CoV-2 patients. These devices proved to be well-tolerated and easy to be used. Further studies on a larger number of subjects are needed in order to possibly confirm these preliminary results.
Keywords: COVID-19; SARS-CoV-2 infection; nasal lavage; nasal swab; upper airways infection.
. 2021 Dec 6;12:794471.
doi: 10.3389/fneur.2021.794471. eCollection 2021.
The Effect of Isotonic Saline Nasal Lavages in Improving Symptoms in SARS-CoV-2 Infection: A Case-Control Study
Giacomo Spinato[SUP] 1 [/SUP], Cristoforo Fabbris[SUP] 2 [/SUP], Giulio Costantini[SUP] 3 [/SUP], Federica Conte[SUP] 3 [/SUP], Pier Giorgio Scotton[SUP] 2 [/SUP], Francesco Cinetto[SUP] 1 [/SUP], Rosalba De Siati[SUP] 1 [/SUP], Alessandro Matarazzo[SUP] 1 [/SUP], Marco Citterio[SUP] 1 [/SUP], Giacomo Contro[SUP] 1 [/SUP], Cosimo De Filippis[SUP] 1 [/SUP], Carlo Agostini[SUP] 1 [/SUP], Enzo Emanuelli[SUP] 2 [/SUP], Paolo Boscolo-Rizzo[SUP] 4 [/SUP], Daniele Frezza[SUP] 2 [/SUP]
Affiliations
- PMID: 34938268
- PMCID: PMC8687114
- DOI: 10.3389/fneur.2021.794471
Abstract
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mainly colonizes nasopharynx. In upper airways acute infections, e.g., the common cold, saline nasal irrigations have a significant efficacy in reducing symptoms. The present study aimed to test the efficacy of nasal lavages in upper airways symptoms of Coronavirus Disease 2019 (COVID-19). Methods: A series of consecutive adult subjects who tested positive for SARS-CoV-2 from December 2020 to February 2021 performed daily nasal lavages with saline solution (Lavonase®-Purling, Lugo di Romagna, Italy) for 12 days, starting on the day after the SARS-CoV-2 positive swab. A control group included a historical series of patients who were infected in February-March 2020 and who did not perform lavages. An ad hoc questionnaire regarding symptoms was administered to each subjects at base-line and 10 days after diagnosis (i.e., on the same day of the control swab) in both cases and controls. Results: A total of 140 subjects were enrolled. 68 participants in the treatment group and 72 in the control group were included. 90% of respondents declared the lavages were simple to use and 70% declared they were satisfied. Symptoms of blocked nose, runny nose, or sneezing decreased by an average of 24.7% after the treatment. Blocked nose and sneezing increased in the same period of time in the control group. Ears and eyes symptoms, anosmia/ageusia symptoms, and infection duration (10.53 days in the treatment group and 10.48 days in the control group) didn't vary significantly among the two groups. Conclusion: Nasal lavages resulted to significantly decrease nasal symptoms in newly diagnosed SARS-CoV-2 patients. These devices proved to be well-tolerated and easy to be used. Further studies on a larger number of subjects are needed in order to possibly confirm these preliminary results.
Keywords: COVID-19; SARS-CoV-2 infection; nasal lavage; nasal swab; upper airways infection.